摘要
目的:探讨厄贝沙坦治疗高血压伴心力衰竭的疗效及其对血清hs-CRP和BNP水平的影响。方法:将我院收治的96例高血压伴心力衰竭患者随机分为两组。对照组采取常规内科治疗措施,试验组在对照组基础上加用厄贝沙坦治疗。比较两组临床疗效及hs-CRP、BNP水平。结果:试验组心力衰竭总有效率为95.8%,显著高于对照组的79.2%,差异有统计学意义(P<0.05);治疗后试验组hs-CRP、BNP水平降低,显著低于对照组,差异有统计学意义(P<0.05)。结论:厄贝沙坦治疗高血压伴心力衰竭的效果显著,具有较高的临床有效率,有效降低患者hs-CRP、BNP水平,提高生存质量,值得临床选择。
Objective： to study irbesartan treatment the curative effect of hypertension with heart failure and its influence on serum hs-BNP and CRP level; Methods： our hospital 96 cases of hypertension with heart failure patients were randomly divided into two groups.Control group of 48 cases of conventional medical treatment measures,and on the basis of 48 cases in the control group and test group treated with irbesartan. Compare two groups of patient＇s clinical curative effect and the hs- differences in the levels of CRP,the BNP;Results： the experimental group for heart failure patients with total effective rate of 95.8% to 79.2%,significantly higher than the control group is statistically significant（P0.05）; After treatment group patients with hs CRP,BNP levels drop,the control group,was also significantly lower than the same period comparison were statistically significant（P 0.05）; Conclusion： irbesartan treatment of hypertension with heart failure effect is remarkable,it has high clinical efficient,effectively reduce the patients＇ hs- CRP,BNP levels,thus to improve the quality of life and health of body and mind,worth clinical choice.
出处
《北方药学》
2016年第1期106-107,共2页
Journal of North Pharmacy
